LILRB4, SEMA4A, ITGB7, CD70, and CCR1 are particularly promising based on their selective expression, roles in MM pathogenesis, and accessibility for therapeutic targeting (Supplementary Table S1, Table 3). Here, SEMA4A is linked to Miyoshi myopathy.